These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 6957154)

  • 41. A clofibrate controlled trial of gemfibrozil in the treatment of hyperlipidaemias.
    Tuomilehto J; Salonen J; Kuuisto P; Virtamo J; Manninen V; Mälkönen M
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):38-40. PubMed ID: 798195
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
    Maxwell RE; Nawrocki JW; Uhlendorf PD
    Atherosclerosis; 1983 Sep; 48(3):195-203. PubMed ID: 6579963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
    Circulation; 1984 May; 69(5):1067A-1090A. PubMed ID: 6368042
    [No Abstract]   [Full Text] [Related]  

  • 44. Gemfibrozil--the effect of biliary cholesterol saturation of a new lipid-lowering agent and its comparison with clofibrate.
    Hall MJ; Nelson LM; Russell RI; Howard AN
    Atherosclerosis; 1981 Jul; 39(4):511-6. PubMed ID: 6942844
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease.
    Kuo PT; Wilson AC; Kostis JB; Moreyra AB; Dodge HT
    Am Heart J; 1988 Jul; 116(1 Pt 1):85-90. PubMed ID: 3164977
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
    Olivier P; Plancke MO; Marzin D; Clavey V; Sauzieres J; Fruchart JC
    Atherosclerosis; 1988 Mar; 70(1-2):107-14. PubMed ID: 3162679
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. I. Changes in lipid levels after treatment (the "net" reduction)].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Jamska B; Nowacki G
    Przegl Lek; 1987; 44(12):828-36. PubMed ID: 3330252
    [No Abstract]   [Full Text] [Related]  

  • 48. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia.
    Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F
    J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.
    Frick MH; Elo O; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P; Manninen V
    N Engl J Med; 1987 Nov; 317(20):1237-45. PubMed ID: 3313041
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of gemfibrozil on serum lipids in diabetic patients.
    Konttinen A; Kuisma I; Ralli R; Pohjola S; Ojala K
    Ann Clin Res; 1979 Dec; 11(6):240-5. PubMed ID: 398183
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gemfibrozil increases both apo A-I and apo E concentrations. Comparison to other lipid regulators in cholesterol-fed rats.
    Krause BR; Newton RS
    Atherosclerosis; 1986 Jan; 59(1):95-8. PubMed ID: 3081014
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Gemfibrozil Study.
    Manninen V
    Acta Med Scand Suppl; 1985; 701():83-8. PubMed ID: 3907298
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of common lipoprotein disorders.
    Brown WV; Goldberg IJ; Ginsberg HN
    Prog Cardiovasc Dis; 1984; 27(1):1-20. PubMed ID: 6330792
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The diagnosis and management of hyperlipidemia.
    Gotto AM; Jones PH; Scott LW
    Dis Mon; 1986 May; 32(5):245-311. PubMed ID: 3519132
    [No Abstract]   [Full Text] [Related]  

  • 56. Dietary and drug treatment of hyperlipoproteinemia.
    Mordasini R; Oster P; Riesen W
    Ric Clin Lab; 1982; 12(1):117-25. PubMed ID: 7046017
    [No Abstract]   [Full Text] [Related]  

  • 57. Gemfibrozil for hyperlipidemia.
    Med Lett Drugs Ther; 1982 Jun; 24(612):59-60. PubMed ID: 6953310
    [No Abstract]   [Full Text] [Related]  

  • 58. Rational drug therapy of the hyperlipoproteinemias, Part II.
    Blum CB; Levy RI
    Ration Drug Ther; 1986 Oct; 20(10):1-4. PubMed ID: 3472266
    [No Abstract]   [Full Text] [Related]  

  • 59. Different patterns of postprandial lipoprotein metabolism in normal, type IIa, type III, and type IV hyperlipoproteinemic individuals. Effects of treatment with cholestyramine and gemfibrozil.
    Weintraub MS; Eisenberg S; Breslow JL
    J Clin Invest; 1987 Apr; 79(4):1110-9. PubMed ID: 3470306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
    Nash DT
    Postgrad Med; 1983 Apr; 73(4):75-82. PubMed ID: 6572892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.